In a cross-sectional analysis conducted in preclinical AD, a plasma biomarker panel consisting of GFAP, p-tau181, and p-tau231 exhibited increased levels in CU Aβ-positron emission tomography (PET)-positive individuals compared to those who tested negative [112]. This evidence concerns the gene GFAP and Alzheimer disease.